Boston Scientific Drops 4% as Q3 Results Put Guidance in Focus
As seen on the 24/7 Wall St. homepage on October 28, 2026.
A 4% slide to $40.27 on the day Q3 results landed puts the $58 billion device maker's guidance under the microscope. Moves this size are rare for a name that usually trades like a steady compounder.
Continue ReadingShow less
Boston Scientific slid just over 4% to $40.27 on the day it reported third-quarter results, a rare single-session move for a stock long treated as a steady compounder in medical devices.
A sharp same-day drop after earnings signals that the headline numbers, the forward guidance, or both fell short of what investors were positioned for.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
At roughly 58 billion dollars in market capitalization, Boston Scientific is a widely held large-cap, so a move of this size reflects a reassessment of the growth trajectory and puts management's guidance commentary front and center.
Whether the guidance was revised, maintained, or tightened determines if this selloff is an entry point or a durable reset in expectations, so investors will be watching the commentary closely.
Sources
Mentioned: BSX